Release date: 2014-07-10
Bao Laite issued a notice on the evening of June 30, saying that it will increase its capital to support Boao Tiansheng and enter the field of hemodialysis. In addition to Bao Laite, Xinhua Medical, Shandong Weigao, Hejia shares, Jiangxi Sanxin and many other listed companies have also frequently invested heavily in the field of hemodialysis. From the medical equipment quality Miles activities, it is understood that, guided by domestic policies, the hemodialysis field will become a new profit growth point for the medical device industry in the future.
The proportion of medical insurance reimbursement for kidney disease patients exceeded 90%
"As the national policy has tilted the hemodialysis patients and the reimbursement rate has increased, we are very optimistic about this market." Zhao Yixin, chairman of Xinhua Medical, said that the company will build 10 hemodialysis centers this year, 20 will be built next year, and 30 will be built in 2016. Home, and supporting the construction of two kidney disease specialist hospitals as the flagship store of the dialysis center. It is planned that by 2020, the company's hemodialysis product line will have an overall revenue of more than 1 billion yuan, including equipment, consumables and hemodialysis centers, to achieve industrial integration.
The hemodialysis machine uses a manual method to imitate the filtering effect of the human kidney. In the case of extracorporeal circulation, the balance of water and electrolyte is adjusted by removing excess nitrogen compounds, metabolic products or overdose drugs in the blood of the human body. Achieve therapeutic purposes.
Hemodialysis and peritoneal dialysis are currently the most common alternative treatments for end-stage renal disease. Hemodialysis concentrate, hemodialysis dry powder, dialyzer and dialysis pipeline are the consumable products for hemodialysis treatment. They are routine blood purification treatment products for patients with kidney disease, so the quality requirements of the products are particularly prominent and important.
Zhao Yixin believes that the hemodialysis industry is an industry encouraged by the state. The national medical insurance is gradually increasing the proportion of treatment reimbursement for patients with kidney disease, thus ensuring the basic survival rights of patients. At the same time, the industry is in industry planning, policy support, government procurement, etc. Received the attention and support of the national and local governments.
"At present, the treatment rate of patients with end-stage renal disease in China is low, and the distribution area of ​​treatment is extremely unbalanced. The state is encouraging the development of the hemodialysis industry. Medical insurance is gradually increasing the proportion of treatment reimbursement for patients, and at the same time in industry planning and policy. Support and government procurement have received the attention and support of the state and local governments." Zhao Yixin pointed out.
It is reported that on August 30, 2012, the National Development and Reform Commission, the Ministry of Health, the Ministry of Finance, the Ministry of Human Resources and Social Welfare, the Ministry of Civil Affairs, and the Insurance Regulatory Commission announced the "Guiding Opinions on the Implementation of Major Disease Insurance for Urban and Rural Residents", clearly pointing out Eight types of major patients with end-stage renal disease (uremia) are guaranteed. At present, through the connection between the new rural cooperative medical system and medical assistance, the level of supplementation of these diseases is about 90%.
Medical device companies have been involved in the hemodialysis industry
Affected by the policy, many domestic listed companies have invested in the hemodialysis industry, and the earliest promoters are Shandong Weigao and Baolaite.
At present, the domestic market coverage of domestic “disposable hemodialysis tubing†and “disposable arteriovenous needle†consumables is about 60%, and there are about 10 manufacturers with product registration certificates, mainly in Guangdong, Jiangsu and Shandong. And Sichuan and other regions, among which competitive manufacturers include Guangzhou Bain, Guangdong Lily, Ningbo Tianyi, Jiangxi Sanxin and Sichuan Nangel, etc., accounting for 70% to 80% of the market share.
Chen Xueli, chairman of Shandong Weigao Group, said that at present, Weigao Group's hemodialysis products are complete in terms of equipment, pipelines and dialysate. And also formed a good market sales channel. The Weigao Group's 2013 annual report shows that sales of hemodialysis consumables and equipment are 560 million yuan, an increase of 39.5% over last year. The attributable profit of Weigao Nikkiso Dialysis Machine Co., Ltd., which holds 51% of the shares of Weigao Group, was 6.82 million yuan. The second production line of Synthetic Membrane Dialyzer purchased by Weigao invested 100 million yuan has been put into production, and three and four production lines are expected to be put into operation in the second half of 2014.
Since 2012, Bao Laite has launched a plan to lay out the hemodialysis market. When he acquired Tianjin Yuxin Hongda Medical Device Development Co., Ltd. in 2012, he began to enter the field of hemodialysis.
Bao Laite said on June 12 that in 2013, the company's hemodialysis business achieved good results through epitaxial mergers and acquisitions. Hemodialysis equipment and consumables achieved sales of 60.129 million yuan for the whole year, an increase of 212.56% over the same period of the previous year. In 2014, the company will focus on improving the hemodialysis industry chain and accelerate the layout of the hemodialysis industry.
The hemodialysis market is China's most promising blue ocean market with at least five times the added value. With the gradual liberalization of the qualification of private hemodialysis services, the hemodialysis industry is about to usher in the golden investment period of private capital. According to the theoretical incidence rate, the number of patients in the middle and late stages of China is nearly 2 million, calculated according to the annual dialysis cost of 70,000 yuan, and the market size of the hemodialysis is over 100 billion. At present, there are only about 300,000 patients with regular dialysis, and the treatment rate is less than 15%, which also provides a broad space for the growth of the industry.
Dialyzers, dialyzers are all dependent on imports
Despite the hot investment, there are still many bottlenecks in the domestic hemodialysis market that need to be broken. For example, dialyzers are almost occupied by foreign brands and all imported dialyzer materials.
In the National Medical Extracorporeal Circulation Equipment Standardization Technical Committee and the Laboratory of Guangdong Medical Device Quality Supervision and Inspection Institute, the hemodialysis machines listed there are all imported brands including Fresenius except for one from the Weigao Group. , Jinbao, Bereng and other products.
"The price of imported products is about 100,000 yuan, and the domestically produced ones may have 60,000 yuan." The relevant personnel of the inspection institute pointed out that there are few domestic equipment manufacturers.
There are 5 domestic manufacturers of hemodialysis equipment registration certificates and 4 manufacturers with multi-function pump registration certificates, all of which are located in Chongqing, Guangdong and Shandong. The current market share is relatively low, mainly because of the certain gaps in its products in terms of technology, product support and product quality.
It is reported that the Weigao Group does not have the equipment research and development capabilities, and the hemodialysis equipment is produced in cooperation with the Japanese company. Zhao Yixin believes that Xinhua Medical has its own advantages in medical equipment research and development, and may soon get a registration certificate.
On June 13, the Ministry of Commerce issued an announcement to decide on anti-dumping investigations on imported hemodialysis machines originating in the EU and Japan. Since the first anti-dumping case in China in 1997, until the end of 2011, the Ministry of Commerce filed a total of 69 anti-dumping investigations on imported products. The hemodialysis case was the first time to file a low-cost dumping of “pure medical equipmentâ€.
The investigation by the Ministry of Commerce stems from the application of the anti-dumping investigation submitted by Chongqing Shanwaishan Technology Co., Ltd., which was founded by Gao Guangyong, and the other three companies to the Ministry of Commerce. According to the national blood purification case information registration data, more than 90% of hemodialysis equipment and more than 80% of hemodialysis consumables are imported products. This huge market has long been occupied by importers.
In addition, the materials in the dialyzer are almost all imported, and domestically produced has not yet been developed. The relevant person in charge of the Guangdong Provincial Medical Device Quality Supervision and Inspection Institute said that the country has been unable to break through in this respect, and the quality of domestic products is still very different from the quality of imported products.
However, Zhao Yixin believes that "this is not static. With the rapid development of the hemodialysis market, domestic products are supported by talents, capital, management, and product technology and quality. The material problem can be broken."
"If the equipment and pipelines are all provided by domestic enterprises, the average cost of dialysis can be reduced by about 100 yuan per day," said a senior executive of the Weigao Group.
Source: China News Network
Smart Door Lock,Smart Security Door Locks,Fingerprint Smart Door Lock,Electronic Key Card System Smart Lock
Chongqing Huifan Technology Co.,Ltd. , https://www.huifantech.com